These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33213378)

  • 1. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial.
    Tang J; Wang Y; Han T; Mao Q; Cheng J; Ding H; Shang J; Zhang Q; Niu J; Ji F; Chen C; Jia J; Jiang X; Lv N; Gao Y; Wang Z; Wei Z; Chen Y; Zeng M; Mao Y
    BMC Gastroenterol; 2020 Nov; 20(1):391. PubMed ID: 33213378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial.
    Wang YF; Tang JT; Han T; Ding HG; Ye WJ; Wang MR; Cheng J; Yang YP; Chen CW; Xie Q; Mao Q; Niu JQ; Wang ZH; Wei Z; Chen YX; Zeng M; Mao YM
    J Dig Dis; 2018 Mar; 19(3):144-154. PubMed ID: 29389068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.
    Uojima H; Hidaka H; Nakayama T; Sung JH; Ichita C; Tokoro S; Masuda S; Sasaki A; Koizumi K; Egashira H; Kako M
    World J Gastroenterol; 2017 Dec; 23(45):8062-8072. PubMed ID: 29259382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):461-70. PubMed ID: 24678622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
    Wang S; Zhang X; Han T; Xie W; Li Y; Ma H; Liebe R; Weng H; Ding HG
    BMC Gastroenterol; 2018 Sep; 18(1):137. PubMed ID: 30180806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema.
    Sakaida I; Yamashita S; Kobayashi T; Komatsu M; Sakai T; Komorizono Y; Okada M; Okita K;
    J Int Med Res; 2013 Jun; 41(3):835-47. PubMed ID: 23685892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio.
    Komiyama Y; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Yasui Y; Tamaki N; Takada H; Higuchi M; Gotou T; Kubota Y; Takaura K; Hayashi T; Oh W; Okada M; Enomoto N; Izumi N
    PLoS One; 2017; 12(3):e0174649. PubMed ID: 28362879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study.
    Sakaida I; Yanase M; Kobayashi Y; Yasutake T; Okada M; Okita K;
    J Int Med Res; 2012; 40(6):2381-93. PubMed ID: 23321196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.
    Okita K; Sakaida I; Okada M; Kaneko A; Chayama K; Kato M; Sata M; Yoshihara H; Ono N; Murawaki Y
    J Gastroenterol; 2010 Sep; 45(9):979-87. PubMed ID: 20387081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tolvaptan in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials.
    Chai L; Li Z; Wang T; Wang R; Pinyopornpanish K; Cheng G; Qi X
    Expert Rev Gastroenterol Hepatol; 2023; 17(10):1041-1051. PubMed ID: 37794713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
    Zhang X; Wang SZ; Zheng JF; Zhao WM; Li P; Fan CL; Li B; Dong PL; Li L; Ding HG
    World J Gastroenterol; 2014 Aug; 20(32):11400-5. PubMed ID: 25170228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curative Effect and Safety of Tolvaptan Combined With Traditional Diuretics in Treatment of Patients With Cirrhotic Ascites and Relevant Research on Its Dose.
    Li X; Liu S; Xu H; Zhou W
    Am J Ther; 2023 Mar-Apr 01; 30(2):158-162. PubMed ID: 33416254
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites.
    Shigefuku R; Iwasa M; Eguchi A; Tempaku M; Tamai Y; Suzuki T; Takei Y
    Intern Med; 2021; 60(21):3359-3368. PubMed ID: 34719623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan.
    Iwasa M; Ishihara T; Kato M; Isoai A; Kobayashi R; Torii N; Soneda N; Takei Y
    Intern Med; 2019 Nov; 58(21):3069-3075. PubMed ID: 31292400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study.
    Shiba S; Chu PS; Nakamoto N; Yamataka K; Taniki N; Ojiro K; Yamaguchi A; Morikawa R; Yoshida A; Ikura A; Ebinuma H; Saito H; Kanai T
    BMC Gastroenterol; 2020 Mar; 20(1):53. PubMed ID: 32138675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Tajiri K; Tokimitsu Y; Ito H; Atarashi Y; Kawai K; Minemura M; Yasumura S; Takahara T; Shimizu Y; Sugiyama T
    Dig Dis; 2018; 36(4):314-321. PubMed ID: 29852495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites.
    Kida Y
    Dig Dis; 2019; 37(3):239-246. PubMed ID: 30625470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.
    Nakanishi H; Kurosaki M; Hosokawa T; Takahashi Y; Itakura J; Suzuki S; Yasui Y; Tamaki N; Nakakuki N; Takada H; Higuchi M; Komiyama Y; Yoshida T; Takaura K; Hayashi T; Kuwabara K; Sasaki S; Izumi N
    J Gastroenterol; 2016 Jun; 51(6):620-7. PubMed ID: 26610908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of continued administration of tolvaptan on cirrhotic patients with ascites.
    Kogiso T; Sagawa T; Kodama K; Taniai M; Tokushige K
    BMC Pharmacol Toxicol; 2018 Dec; 19(1):87. PubMed ID: 30563565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.
    Goto A; Terai S; Nakamura M; Matsumoto M; Sakaida I
    Clin J Gastroenterol; 2015 Feb; 8(1):47-51. PubMed ID: 25475138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.